Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients with High-Risk Prostate Cancer

Description

This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients with High-Risk Prostate Cancer

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients with High-Risk Prostate Cancer

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Detroit

Henry Ford Cancer Pavilion, Detroit, Michigan, United States, 48202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Men, age greater than or equal to 18 years of age.
  • 2. Men who racially identify as black or multiracial including black
  • 3. Diagnosis of prostate cancer of any histology.
  • 4. Must meet NCCN guidelines for germline testing
  • 1. Men with very low, low or intermediate risk prostate per NCCN guidelines with a positive family history or intraductal histology. Family history here is considered significant if the patient has:
  • * a first degree relative with prostate cancer or more than one first/second degree relative with prostate cancer, or
  • * ≥3 cancers on same side of family, especially diagnoses ≤50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, or urothelial cancer
  • 2. Men with high-risk, very-high risk (per NCCN definitions of risk groups), lymph node positive, or metastatic prostate cancer independent of family history of histology.
  • 1. Have had prior germline testing.
  • 2. Have somatic genetic testing that is positive for a possible germline variant.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Henry Ford Health System,

Study Record Dates

2026-06